---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265800"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:25:29.609064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib

## Summary
- Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.
- Net loss $72.0M in Q3 2025 vs $16.6M loss in Q3 2024; revenue fell to $0.3M from $29.1M.
- European Medicines Agency accepted MAAs for obicetrapib monotherapy and FDC with ezetimibe.
- R&D expenses $31.0M (down 13% YoY); SG&A $24.5M (up 33% YoY), driven by personnel and share-based compensation.
- Ongoing Phase 3 trials: PREVAIL CVOT (>9,500 enrolled), REMBRANDT plaque imaging, and RUBENS (diabetes) expected Q4 2025.

## SEC filing metadata
- accession: 0001193125-25-265800
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/0001193125-25-265800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265800
- JSON: https://secwatch.observer/filing/0001193125-25-265800.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.